pharmacokinetics and toxicity of linezolid in MDR-TB patients

pharmacokinetics and toxicity of linezolid in MDR-TB patients - Linezolid in MDR-TB

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON29905

Enrollment

Registered

2006-09-28

Start date

2006-09-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tuberculosis MDR-TB

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: MDR-TB attending physician initiates treatment with linezolid

Exclusion criteria

Exclusion criteria: allergy for linezolid

Design outcomes

Primary

Measure	Time frame
-Primary: PK of linezolid in MDR-TB patients	—

Secondary

Measure	Time frame
-Secondary: toxicity related to linezolid; i.e. anemia, and neurotoxicity	—

Countries

Netherlands

Outcome results